The tool identifies high-risk patients, creates care pathways, and alerts doctors, nursing staff, and palliative care teams ...

To address the unmet need for a cure for RTT, the therapeutic potential of adult Neural Precursor Cells (NPCs) was ...

RGX-121 has been evaluated in the Phase I/II/III CAMPSIITE study as a one-time gene therapy treatment for Hunter syndrome.

D Molecular Therapeutics reported its experimental gene therapy demonstrated a nearly 90% reduction in the need for ...

The Cell & Gene Therapy manufacturing Services market is driven by increasing investments in advanced therapies, rising ...

Ocugen, Inc. (NASDAQ: OCGN) has announced that its Chief Scientific Officer, Dr. Arun Upadhyay, will be a featured speaker at ...

FLT-201 is a gene therapy commercialized by Spur Therapeutics, with a leading Phase II program in Gaucher Disease Type I.

Can you stop LCA, a form of blindness caused by a change in a single base pair, simply by injecting a viral vector with the right ... indicated that the visual pathway indeed retains the ability ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced ...

Transmission of an infectious disease may occur through one or more of diverse pathways including physical ... airborne inhalation, or through vector-borne spread. The term infectivity describes ...

AAV-AQP1 is a gene therapy commercialized by MeiraGTx, with a leading Phase II program in Sicca Syndrome (Sjogren).